NL-OMON49087已完成不适用
Anti-Xa trough levels for therapeutic LMWH treatment monitoring, a pilot study - NXT level
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Adult hospitalized patients receiving nadroparin in therapeutic doses for a
- •period of *3days, written informed consent.
排除标准
- •Patients on CVVH, peritoneal dialysis, or ECMO. Patients with congenital
- •coagulation disorders.
研究者
相似试验
已完成
不适用
Anti-Xa activity after a reduced therapeutic dose of nadroparin in patients with renal impairment using a dosage guideline of the Dutch Federation of NephrologyRenal impairment10038430coagulation10014523NL-OMON44475Medisch Centrum Leeuwarden194
Unknown
不适用
Anti-Xa activity of nadroparin after a dose reduction (XANDO)Renal impairmentVenous thromboembolism NierinsufficiëntieVeneuze trombo-embolieNL-OMON23816Medisch Centrum Leeuwarden194
Unknown
不适用
Anti Xa Activity in Cancer Patients Receiving Low-molecular-weight Heparin for Venous ThromboembolismNeoplasmsVenous ThromboembolismNCT02898051Assistance Publique - Hôpitaux de Paris370
已完成
不适用
The serum anti-Xa activity monitoringatrial fibrillationJPRN-UMIN000020761Keio University School of Medicine100
进行中（未招募）
1 期
HEAT-AML (Hydroxyurea-Enhanced Ara-C Treatment of Adult Acute Myeloid Leukaemia): A clinical study to assess whether addition of hydroxyurea to standard treatment against acute myeloid leukaemia (AML) is safe and efficaciousewly diagnosed acute myeloid leukaemia (AML) in patients = 18 years of ageCTIS2023-509019-97-00Karolinska University Hospital69